摘要
目的观察益肾康颗粒治疗慢性移植肾肾病(CAN)及对外周血T淋巴细胞亚群的影响。方法将120例确诊为早期CAN患者分为益肾康组和对照组,两组均维持常规治疗,益肾康组加服益肾康颗粒30g/d,观察治疗第4、8、12周后外周血中CD3+、CD4+、CD8+水平,并计算出CD4+/CD8+的比值,分析益肾康颗粒对T淋巴细胞亚群的影响及与对照组的差异。结果治疗前两组水平相近(P>0.05);治疗后益肾康组的外周血CD4+、CD8+计数及CD4+/CD8+比值均明显高于对照组,差异有统计学意义(P<0.05)。益肾康组间各指标比较差异有统计学意义(P<0.05)。治疗期间未见严重的副作用。结论益肾康颗粒能够提高T淋巴细胞亚群的水平,调节肾移植术后抗排斥和感染之间的矛盾,辅助治疗CAN。
Objective To observe the therapeutic effect of Yishenkang Granules in the treatment of chronic allograft nephropathy （CAN） and the impact of peripheral blood T lymphocyte subsets. Methods 120 cases with early CAN patients were divided into Yishenkang group and control group, both groups were maintained for conventional treatment, Yishenkang group was added Yishenkang granules 30 g/d, the exchanges of peripheral blood CD3^＋, CD4^＋, CD8^＋ were observed 4, 8, 12 weeks after treatment respectively. Then the ratio of CD4^＋/CD8^＋ was calculated, and the effect of Yishenkang Granule on T lymphocyte subsets and difference from control group were analyzed. Results The level of two groups before treatment was similar （P 〉 0.05）; the exchanges with Yishenkang group of peripheral blood CD4＋, CD8~ count and CD4~/CD8~ ratio were significantly higher than those in the control group, there were significant differences （P 〈 0.05）. The exchanges of indices in Yishenkang group had significant difference （P 〈 0.05）; no severe side effects occurred during treatment. Conclusion Yishenkang Granules can improve T lymphocyte subsets levels, regulate the balance between rejection and infection of the contradiction after renal transplantation, and adjuvant therapy for CAN.
出处
《中国医药导报》
CAS
2013年第7期107-109,共3页
China Medical Herald
基金
河南省科技攻关计划项目(项目编号:102102310148)
关键词
益肾康颗粒
慢性移植肾肾病
T淋巴细胞亚群
Yishenkang Granule
Chronic allograft nephropathy
T lymphocyte subsets
